A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy Journal Article
| Authors: | Haese, A.; Tin, A. L.; Carlsson, S. V.; Sjoberg, D. D.; Pehrke, D.; Steuber, T.; Huland, H.; Graefen, M.; Scardino, P. T.; Schlomm, T.; Vickers, A. J.; Lilja, H.; Sauter, G. |
| Article Title: | A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy |
| Abstract: | Background: A pre-specified model based on four kallikrein markers in blood, commercially available as 4Kscore, predicts Gleason Grade (GG) 3 + 4 or higher prostate cancer on biopsy. However, sampling error and variation in pathology reporting may miss aggressive disease. Methods: The 4Kscore was measured in cryopreserved blood from 2330 men obtained before prostatectomy at a single institution between 2002 and 2010. Adverse surgical pathology and biochemical recurrence (BCR) were pre-specified to be assessed in all men, biopsy GG 3 + 3, and 3 + 4. Results: Adjusted for established clinical predictors, the 4Kscore was significantly associated with adverse pathology (OR 1.49; 95% CI 1.32, 1.67; p < 0.0001). Adding 4Kscore increased discrimination from (AUC) 0.672 to 0.718 and 0.644 to 0.659 within biopsy GG 3 + 3 and 3 + 4, respectively. Higher 4Kscore was associated with higher risk of BCR (HR 1.16, 95% CI 1.06, 1.26; p = 0.001). Adding 4Kscore improved the prediction of BCR (C-index 0.630–0.660) within GG 3 + 3, but not GG 3 + 4. Conclusions: The 4Kscore can help guide the clinical decision whether additional risk assessment—such as confirmatory biopsy—is needed to decide between active surveillance versus curative therapy. Evidence that the panel could influence management in biopsy GG 3 + 4 is less strong and requires further investigation. © 2020, The Author(s), under exclusive licence to Cancer Research UK. |
| Keywords: | adult; human tissue; middle aged; major clinical study; recurrence risk; cancer diagnosis; diagnostic accuracy; biological marker; retrospective study; prediction; high risk patient; prostate cancer; gleason score; cryopreservation; prostatectomy; prostate biopsy; kallikrein; diagnostic test; biochemical recurrence; diagnostic test accuracy study; blood storage; human; male; priority journal; article; 4kscore test |
| Journal Title: | British Journal of Cancer |
| Volume: | 123 |
| Issue: | 4 |
| ISSN: | 0007-0920 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2020-08-18 |
| Start Page: | 604 |
| End Page: | 609 |
| Language: | English |
| DOI: | 10.1038/s41416-020-0914-7 |
| PUBMED: | 32467601 |
| PROVIDER: | scopus |
| PMCID: | PMC7434907 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work